Citius Pharmaceuticals: CTXR – Pursuing a New Standard of Care

About Citius Pharmaceuticals

Pursuing a New Standard of Care

Citius Pharmaceuticals (NASDAQ: CTXRis a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok®CITI-002 (halobetasol-lidocaine formulationand CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care.

Company Highlights

Citius is committed to developing therapies for unmet medical needs with cost-effective products in high growth categories with low developmental risk.

  • Mino-Lok product has advanced to Phase 3 clinical studies.
  • CITI-101 (Mino-Wrap) is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. More information on this product will be coming soon.
  • CITI-002 is being developed for symptomatic relief of hemorrhoids.  CITI-002 combines the high-potency steroid, halobetasol, with lidocaine.
  • Citius has an experienced management team with demonstrated success in developing and commercializing novel pharmaceutical products.